Health
Affinity’s COVID-19 antibodies ready for manufacture for clinical trials – BSA bureau
The study offers a roadmap for speeding development of Monoclonal Antibodies for other diseases; Techniques applied to COVID-19 studies completed Phase 1 Trial
The study offers a roadmap for speeding development of Monoclonal Antibodies for other diseases; Techniques applied to COVID-19 studies completed Phase 1 Trial
Tychan, a Singapore-based clinical-stage biotechnology company focused on developing life-saving treatments through disruptive technologies, announced on 30 July 2020 a publication in New England Journal of Medicine (NEJM) demonstrating the safety and efficacy for TY014, a novel monoclonal antibody candidate treatment for yellow fever (Y…
-
Noosa News17 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
Noosa News15 hours agoNo matter what happens in his Origin debut, history beckons for rookie maroon Robert Toia
-
Noosa News21 hours agoBrisbane Broncos star Reece Walsh says punching friend in face ‘not a good look’
-
General13 hours agoDairy farmers devastated by floods across parts of New South Wales